FDA approves maintenance treatment for recurrent epithelial ovarian, fallopian tube or primary peritoneal cancers

The U.S. Food and Drug Administration has approved Zejula (niraparib) for the maintenance treatment (intended to delay cancer growth) of adult patients with recurrent epithelial ovarian, fallopian… …read more